<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448733</url>
  </required_header>
  <id_info>
    <org_study_id>Coria Combo</org_study_id>
    <nct_id>NCT01448733</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Tolerability of CeraVe® Lotion Followed by Fixed Dose Clindamycin Phosphate 1.2% / Benzoyl Peroxide 2.5% Gel in the Morning in Combination With CeraVe® Lotion Followed by Tretinoin 0.05% Gel in the Evening for the Treatment of Facial Acne Vulgaris.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zeichner, Joshua, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zeichner, Joshua, M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether Cerave lotion followed by Acanya Gel in the
      morning in combination with Cerave lotion followed by Atralin gel in the evening is safe and
      effective for the treatment of acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">October 2011</completion_date>
  <primary_completion_date type="Anticipated">October 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cutaneous Tolerability of Combination Therapy of Acanya Gel with Atralin Gel for the treatment of acne vulgaris</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of skin erythema, scaling, drying, and stinging/burning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Combination Therapy of Acanya Gel with Atralin Gel for the treatment of acne vulgaris</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluation of efficacy as defined as a global assessment of clear or almost clear after 12 weeks of therapy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Acanya Plus Atralin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single, open-label arm treating acne with Cerave lotion plus Acanya gel in the morning in combination with Cerave lotion plus Atralin gel in the evening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening</intervention_name>
    <description>Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening</description>
    <arm_group_label>Acanya Plus Atralin</arm_group_label>
    <other_name>Acanya Gel</other_name>
    <other_name>Atralin Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females ≥ 12 years old.

          -  Subjects must be in good general health as confirmed by medical history and physical
             examination.

          -  Females of child-bearing potential must have a negative urine pregnancy test at the
             baseline visit and agree to be abstinent or use adequate birth control during the
             study (oral contraceptives, Norplant, Depo-Provera, or double barrier methods (e.g.,
             condom and spermicide).

          -  Clear diagnosis of facial acne vulgaris for at least 6 months.

          -  Subject must have a static Physician's Global Assessment (PGA) of 2 (mild severity) or
             3 (moderate severity).

          -  Disease must be stable or slowly worsening for more than one week prior to entering
             the study.

          -  Subjects or their guardians must be able to read, sign, and date the informed consent,
             and abide by study restrictions for its duration.

        Exclusion Criteria:

          -  Females who are pregnant, attempting to conceive, or breastfeeding.

          -  Subjects with known hypersensitivity to any ingredients in the study drugs.

          -  Subjects with overt signs of skin atrophy, telangiectasias or other skin findings that
             would affect efficacy evaluation.

          -  Subjects with a current active skin malignancy or infection.

          -  Subjects requiring the use of medications known to alter the course of acne vulgaris
             during the study treatment.

          -  Subjects who have received systemic antibiotics within 2 weeks.

          -  Subjects using systemic corticosteroids or immunosuppressants within 28 days of
             entering the study.

          -  Subjects who have received any topical therapies for acne vulgaris within 7 days of
             entering the study.

          -  Subjects taking birth control pills used solely for acne control.

          -  Subjects who are currently participating in or, within the previous 28 days, have
             participated in another study for the treatment of acne vulgaris.

          -  Subjects with clinical conditions that may post a health risk to the subject by being
             involved in the study or detrimentally affect regular follow-up of the subject.

          -  Subjects who have Crohn's disease, colitis, or if subjects ever developed colitis or
             severe diarrhea with past antibiotic use.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mt Sinai Hospital, Department of Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2011</study_first_submitted>
  <study_first_submitted_qc>October 6, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>October 6, 2011</last_update_submitted>
  <last_update_submitted_qc>October 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zeichner, Joshua, M.D.</investigator_affiliation>
    <investigator_full_name>Joshua Zeichner</investigator_full_name>
    <investigator_title>Director of Cosmetic and Clinical Research, Mt Sinai Dermatology</investigator_title>
  </responsible_party>
  <keyword>acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
    <mesh_term>Tretinoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

